Floatz logo

Giapreza

Liver Transplant; Complications

University of California, San FranciscoPhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Liver Transplant; Complications cohort.

Asset / SponsorPhaseRating
TACROLIMUS
The Second Hospital of Tangshan
Phase 4BBB
Equine Atg
University Hospital, Toulouse
Phase 4BB
Everolimus
Novartis Pharmaceuticals
Phase 3BB
Semaglutide
University Health Network, Toronto
Phase 4BB
Sitagliptin
University Health Network, Toronto
Phase 4BB

View all 35 →

Same molecule, other indications

Giapreza is also rated in:

acute kidney injuryDormant
BB
Indicative ·
70 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
67 / 100
View asset →
chronic liver failureDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →